Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
Primary Industries
- Drugs
- Dental
- Biotechnology
- Antimicrobial
- Antiseptic
- Dentifrice
- Therapeutic
- Medical
- Diagnostic
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 28916
License Grant
University hereby grants to Licensee an exclusive sublicense right for Licensed Products and/or Licensed Processes under the Licensed Patents.
License Property
The amendment adds the identification of the divisional application of U.S. Patent Number 5,932,469, which divisional is numbered 09/361,900.
Field of Use
5,932,469 The subject invention concerns novel polypeptides and nucleic acid sequences encoding those polypeptides. The polypeptides are related to bacteriocins, e.g. mutacins, produced by microbes for providing a selective advantage for the microbe. The invention includes methods of use which exploit the advantageous activities or properties of the polypeptides or nucleic acid sequences.
The phenotypically similar bacteria collectively known as the mutans streptococci are considered major etiologic agents responsible for dental caries. The species most commonly associated with human disease is Streptococcus mutans. Pathogenicity of S. mutans includes the ability to produce antimicrobial substances generally referred to as bacteriocin-like inhibitory substances (BLIS) or bacteriocins. Bacteriocins produced by Streptococcus mutans are known as mutacins. These substances are produced by microorganisms to provide a selective force necessary for sustained colonization in a milieu of densely packed competing organisms found in dental plaque.
IPSCIO Record ID: 27856
License Grant
University hereby grants to Licensee an exclusive license, limited to the Licensed Field and the Licensed Territory, to make, have made, use and sell Licensed Products and/or Licensed Processes under the Licensed Patents. University agrees that it will not grant any other licenses in the Licensed Field with respect to the Licensed Patents, except that University reserves to itself and the University of Florida the right to make, use and sell Licensed Products and/or Licensed Processes under the Licensed Patents solely for research purposes, including research for any sponsors.
License Property
Licensed the intellectual property is the MU 1140 antibiotic technology.
'Licensed Patents' shall refer to and mean all of the following UFRF intellectual property the United States Patent Number 5,932,469 entitled 'Antimicrobial Polypeptide and Methods of Use' and any and all United States patents and foreign patents issuing from patent applications based in all or in part upon technology disclosed in the '469 patent.
Field of Use
'Licensed Field' shall be limited to the field of healthcare and food.
IPSCIO Record ID: 25952
License Grant
The amended license agreement provides the Company with an exclusive worldwide license to make, use and sell products and processes covered by Patent No. 5,607,672, entitled “Replacement Therapy for Dental Cariesâ€, which was filed in the U.S. PTO on June 7, 1995 and made effective on March 4, 1997. The patent will expire on June 7, 2015.
IPSCIO Record ID: 290838
License Grant
The University grants a license for certain patents for new drug product development. The Licensee is granted exclusive license to the proprietary STAMP platform pursuant to the terms of an exclusive license agreement, including rights to develop and commercialize any products developed using the STAMP platform.
License Property
The property is several patents for in both the Human Dental and Human Medical fields.
Specifically Targeted Antimicrobial Peptides (STAMPs) are designed by first identifying targeting domains in bacterial genomes using genomic mining techniques. An antimicrobial peptide is then linked to the targeting domain, directing the antimicrobial activity to a specific pathogen or group of pathogens of choice within a microbial community. The platform technology allows the STAMP to effectively re-engineer the microbiota by selectively killing the targeted pathogen while sparing the remaining healthy microorganisms within the indigenous microflora. In contrast to this targeted approach, broad-spectrum antibiotics indiscriminately kill both beneficial and pathogenic bacteria. Treatment with STAMPs results in biofilm communities that remain intact and “healthier†after treatment, serving as a barrier to prevent reinfection.
Field of Use
A STAMP platform proof-of-concept has been demonstrated with C16G2 advancing through several clinical trials, including Phase 2 clinical trials, conducted under an IND application. Administered as a topical product, C16G2 targets S. mutans, recognized as the major causative agent of dental caries (tooth decay/cavities). These studies demonstrated an acceptable safety and tolerability profile of the drug while demonstrating a selective reduction of S. mutans in the oral cavity.
C16G2 is now delivered via a gel tray, is being developed for use in preventing tooth decay and cavities under an investigational new drug application with the U.S. Food and Drug Administration.
IPSCIO Record ID: 28035
License Grant
The University or Licensor granted rights to certain patents and technology to the Ireland-based Licensee. The agreement is a royalty-bearing, non-exclusive license under Licensed Subject Matter to manufacture, have manufactured, use, distribute, Sell, offer to Sell, import, lease, loan or otherwise Commercialize Licensed Products in Licensee's ordinary course of business, within the Licensed Territory (worldwide) for use within Licensed Field. This Patent agreement is subsequent to a research agreement from which the relevant technology emerged.
License Property
The Licensed Subject Matter means protein and antibody based inventions. Patent Rights means the University's rights in information or discoveries covered by the University’s patent(s) or patent applications in the Licensed Territory for the following a.“VMP-Like Sequences of Pathogenic Borreliaâ€; and b.“VMP-Like Sequences of Pathogenic Borrelia Species and Strainsâ€; and c.any patent(s) issuing from the foregoing applications; and d.any reissue, extension, revival or reexamination of the foregoing patent(s).
Field of Use
The Licensed Field means the use of Licensed Subject Matter to make, have made, use and Sell a protein or antibody-based human diagnostic test for Lyme disease.
IPSCIO Record ID: 28854
License Grant
University hereby grants to Licensee an exclusive license, limited to the Licensed Field and the Licensed Territory, under the Licensed Patents to make, use and sell Licensed Products and/or Licensed Processes University reserves to itself and the University of Florida the right to make, use and sell Licensed Products and/or Licensed Processes under the Licensed Patents for research purposes, including research for any sponsors.
License Property
'Licensed Patents' shall refer to and mean all of the following UFRF intellectual property the United States Patent Number 5,607,672 entitled 'Replacement Therapy for Dental Caries,' filed in the United States Patent Office on June 7, 1995 and made effective on March 4, 1997, and all United States patents and foreign patents and patent applications based on this U.S. applications.
Field of Use
'Licensed Field' shall be limited to the field of healthcare and food.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
